Uli Hacksell, the former chief executive of Acadia Pharmaceuticals Inc, has been appointed to the board of directors of InDex Pharmaceuticals of Sweden which has a late-stage product for ulcerative colitis. He is being joined on the board by Jesper Wiklund, the company’s former CEO. Professor Hacksell led Acadia for 15 years from the company’s start as a private firm to its listing on Nasdaq. Prior to that, he held executive positions at Astra AB and was president of Astra Draco, one of the company’s research and development subsidiaries.
Mr Wiklund was the InDex Pharmaceuticals CEO from September 2011 to March 2015. He is currently managing director at Oberland Capital.
InDex Pharmaceuticals announced the appointments on 9 July 2015.
Copyright 2015 Evernow Publishing Ltd